Cargando…
Approaches to hepatitis C treatment and cure using NS5A inhibitors
Recent progress in the understanding of hepatitis C virus (HCV) biology and the availability of in vitro models to study its replication have facilitated the development of direct-acting antiviral agents (DAAs) that target specific steps in the viral replication cycle. Currently, there are three maj...
Autores principales: | Kohler, James J, Nettles, James H, Amblard, Franck, Hurwitz, Selwyn J, Bassit, Leda, Stanton, Richard A, Ehteshami, Maryam, Schinazi, Raymond F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949698/ https://www.ncbi.nlm.nih.gov/pubmed/24623983 http://dx.doi.org/10.2147/IDR.S36247 |
Ejemplares similares
-
Studies on the Efficacy, Potential Cardiotoxicity and Monkey Pharmacokinetics of GLP-26 as a Potent Hepatitis B Virus Capsid Assembly Modulator
por: Hurwitz, Selwyn J., et al.
Publicado: (2021) -
Assessment of a Computational Approach to Predict Drug Resistance Mutations for HIV, HBV and SARS-CoV-2
por: Patel, Dharmeshkumar, et al.
Publicado: (2022) -
Asymmetric Binding to NS5A
by Daclatasvir (BMS-790052)
and Analogs Suggests Two Novel Modes of HCV Inhibition
por: Nettles, James H., et al.
Publicado: (2014) -
Synthesis of 4′-Substituted-2′-Deoxy-2′-α-Fluoro Nucleoside Analogs as Potential Antiviral Agents
por: Kasthuri, Mahesh, et al.
Publicado: (2020) -
Raltegravir Is a Potent Inhibitor of XMRV, a Virus Implicated in Prostate Cancer and Chronic Fatigue Syndrome
por: Singh, Ila R., et al.
Publicado: (2010)